Defending Tomorrow – Today

Elusys Therapeutics is dedicated to delivering innovative medical countermeasures that enable fast, effective, and durable protection against infectious agents. Our goal is to accelerate the development and commercialization of novel biodefense solutions, such as our anthrax antitoxin ANTHIM® (obiltoxaximab), for strategic government partners.

ANTHIM® (obiltoxaximab)

Anthrax is a disease caused by Bacillus anthracis and is regarded as a top (“Category A”) biological warfare and bioterrorism threat. Obiltoxaximab is a monoclonal anthrax antitoxin licensed as ANTHIM® in the United States and Canada and as NYXTHRACIS® in Great Britain and the European Union.

ANTHIM® has been delivered to the US Strategic National Stockpile as the result of a successful multi-year partnership with the US government. Elusys was also contracted as of 2022 to deliver ANTHIM to the Public Health Agency of Canada.

Click below to learn more regarding anthrax and our products.